Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis.

Folkerts H, Wierenga AT, van den Heuvel FA, Woldhuis RR, Kluit DS, Jaques J, Schuringa JJ, Vellenga E.

Cell Death Dis. 2019 May 29;10(6):421. doi: 10.1038/s41419-019-1648-4.

2.

Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes.

Yi G, Wierenga ATJ, Petraglia F, Narang P, Janssen-Megens EM, Mandoli A, Merkel A, Berentsen K, Kim B, Matarese F, Singh AA, Habibi E, Prange KHM, Mulder AB, Jansen JH, Clarke L, Heath S, van der Reijden BA, Flicek P, Yaspo ML, Gut I, Bock C, Schuringa JJ, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA.

Cell Rep. 2019 Jan 22;26(4):1059-1069.e6. doi: 10.1016/j.celrep.2018.12.098.

3.

Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia.

Singh AA, Petraglia F, Nebbioso A, Yi G, Conte M, Valente S, Mandoli A, Scisciola L, Lindeboom R, Kerstens H, Janssen-Megens EM, Pourfarzad F, Habibi E, Berentsen K, Kim B, Logie C, Heath S, Wierenga ATJ, Clarke L, Flicek P, Jansen JH, Kuijpers T, Yaspo ML, Valle VD, Bernard O, Gut I, Vellenga E, Stunnenberg HG, Mai A, Altucci L, Martens JHA.

Oncotarget. 2018 May 22;9(39):25647-25660. doi: 10.18632/oncotarget.25429. eCollection 2018 May 22.

4.

Combined HAT/EZH2 modulation leads to cancer-selective cell death.

Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-Megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L.

Oncotarget. 2018 May 22;9(39):25630-25646. doi: 10.18632/oncotarget.25428. eCollection 2018 May 22.

5.

Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.

Folkerts H, Hilgendorf S, Wierenga ATJ, Jaques J, Mulder AB, Coffer PJ, Schuringa JJ, Vellenga E.

Cell Death Dis. 2017 Jul 13;8(7):e2927. doi: 10.1038/cddis.2017.317.

6.

The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.

Mandoli A, Singh AA, Prange KHM, Tijchon E, Oerlemans M, Dirks R, Ter Huurne M, Wierenga ATJ, Janssen-Megens EM, Berentsen K, Sharifi N, Kim B, Matarese F, Nguyen LN, Hubner NC, Rao NA, van den Akker E, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA.

Cell Rep. 2016 Nov 15;17(8):2087-2100. doi: 10.1016/j.celrep.2016.08.082.

7.

Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative Phosphorylation.

Sontakke P, Koczula KM, Jaques J, Wierenga AT, Brouwers-Vos AZ, Pruis M, Günther UL, Vellenga E, Schuringa JJ.

PLoS One. 2016 Apr 7;11(4):e0153226. doi: 10.1371/journal.pone.0153226. eCollection 2016.

8.

Autophagy Proteins ATG5 and ATG7 Are Essential for the Maintenance of Human CD34(+) Hematopoietic Stem-Progenitor Cells.

Gomez-Puerto MC, Folkerts H, Wierenga AT, Schepers K, Schuringa JJ, Coffer PJ, Vellenga E.

Stem Cells. 2016 Jun;34(6):1651-63. doi: 10.1002/stem.2347. Epub 2016 Mar 28.

9.

Convergence of hypoxia and TGFβ pathways on cell cycle regulation in human hematopoietic stem/progenitor cells.

Wierenga AT, Vellenga E, Schuringa JJ.

PLoS One. 2014 Mar 31;9(3):e93494. doi: 10.1371/journal.pone.0093494. eCollection 2014.

10.

CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.

Mandoli A, Singh AA, Jansen PW, Wierenga AT, Riahi H, Franci G, Prange K, Saeed S, Vellenga E, Vermeulen M, Stunnenberg HG, Martens JH.

Leukemia. 2014 Apr;28(4):770-8. doi: 10.1038/leu.2013.257. Epub 2013 Sep 4.

PMID:
24002588
11.

STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells.

Schepers H, Wierenga AT, Vellenga E, Schuringa JJ.

JAKSTAT. 2012 Jan 1;1(1):13-22. doi: 10.4161/jkst.19316. Review.

12.

Tight control of STAT5 activity determines human CD34-derived interstitial dendritic cell and langerhans cell development.

van de Laar L, van den Bosch A, Wierenga AT, Janssen HL, Coffer PJ, Woltman AM.

J Immunol. 2011 Jun 15;186(12):7016-24. doi: 10.4049/jimmunol.1003977. Epub 2011 May 20.

13.

Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.

Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES.

Cancer Res. 2011 Apr 1;71(7):2761-71. doi: 10.1158/0008-5472.CAN-10-0402. Epub 2011 Mar 29.

14.

Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells.

Fatrai S, Wierenga AT, Daenen SM, Vellenga E, Schuringa JJ.

Blood. 2011 Mar 24;117(12):3320-30. doi: 10.1182/blood-2010-08-303669. Epub 2011 Jan 24.

PMID:
21263150
15.

Down-regulation of GATA1 uncouples STAT5-induced erythroid differentiation from stem/progenitor cell proliferation.

Wierenga AT, Vellenga E, Schuringa JJ.

Blood. 2010 Jun 3;115(22):4367-76. doi: 10.1182/blood-2009-10-250894. Epub 2010 Mar 25.

PMID:
20339093
16.

Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses.

Han L, Wierenga AT, Rozenveld-Geugien M, van de Lande K, Vellenga E, Schuringa JJ.

PLoS One. 2009 Nov 24;4(11):e7989. doi: 10.1371/journal.pone.0007989.

17.

Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels.

Wierenga AT, Vellenga E, Schuringa JJ.

Mol Cell Biol. 2008 Nov;28(21):6668-80. doi: 10.1128/MCB.01025-08. Epub 2008 Sep 8.

18.

STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells.

Schepers H, van Gosliga D, Wierenga AT, Eggen BJ, Schuringa JJ, Vellenga E.

Blood. 2007 Oct 15;110(8):2880-8. Epub 2007 Jul 13.

PMID:
17630355
19.

Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis.

Schepers H, Wierenga AT, van Gosliga D, Eggen BJ, Vellenga E, Schuringa JJ.

Blood. 2007 Aug 15;110(4):1317-25. Epub 2007 May 2. Erratum in: Blood. 2007 Oct 15;110(8):2818.

PMID:
17475913
20.

STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBPalpha.

Wierenga AT, Schepers H, Moore MA, Vellenga E, Schuringa JJ.

Blood. 2006 Jun 1;107(11):4326-33. Epub 2006 Feb 2.

PMID:
16455947
21.
22.

Inhibition of the transforming growth factor beta (TGFbeta) pathway by interleukin-1beta is mediated through TGFbeta-activated kinase 1 phosphorylation of SMAD3.

Benus GF, Wierenga AT, de Gorter DJ, Schuringa JJ, van Bennekum AM, Drenth-Diephuis L, Vellenga E, Eggen BJ.

Mol Biol Cell. 2005 Aug;16(8):3501-10. Epub 2005 May 25.

23.
24.

Proteolytic degradation of Smad4 in extracts of AML blasts.

Wierenga AT, Eggen BJ, Kruijer W, Vellenga E.

Leuk Res. 2002 Dec;26(12):1105-11.

PMID:
12443883
25.
26.

The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway.

Birkenkamp KU, Tuyt LM, Lummen C, Wierenga AT, Kruijer W, Vellenga E.

Br J Pharmacol. 2000 Sep;131(1):99-107.

27.
28.

Supplemental Content

Loading ...
Support Center